Clarus Ventures, LLC - Q3 2018 holdings

$425 Million is the total value of Clarus Ventures, LLC's 10 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 25.0% .

 Value Shares↓ Weighting
AVRO  AvroBio Inc.$153,656,000
+81.6%
2,962,3250.0%36.11%
+20.0%
NSTG BuyNanostring Technologies Inc.$71,962,000
+32.9%
4,036,025
+1.9%
16.91%
-12.2%
SIEN  Sientra Inc.$65,211,000
+22.4%
2,730,7650.0%15.33%
-19.1%
FTSV  Forty Seven Inc$56,949,000
-6.7%
3,816,9510.0%13.38%
-38.4%
GRTS NewGritstone Oncology Inc$36,560,0002,567,445
+100.0%
8.59%
ETTX NewEntasis Therapeutics Holdings Inc$17,663,0001,623,405
+100.0%
4.15%
HAIR  Restoration Robotics Inc.$10,353,000
-16.4%
3,569,9860.0%2.43%
-44.8%
VBIV  VBI Vaccines Inc.$6,512,000
-12.0%
2,691,0420.0%1.53%
-41.8%
EPIX  ESSA Pharma Inc.$5,006,000
-20.8%
1,668,5600.0%1.18%
-47.7%
CATB  Catabasis Pharmaceuticals Inc.$1,606,000
-16.6%
2,008,1920.0%0.38%
-45.0%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2018-11-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Nanostring Technologies Inc.20Q3 201860.2%
Sientra Inc.16Q3 201838.2%
Oxford Immunotex Global PLC14Q1 201717.4%
Catabasis Pharmaceuticals Inc.14Q3 201815.3%
VBI Vaccines Inc.10Q3 201811.4%
TetraLogic Pharmaceuticals Corporation9Q4 201512.5%
ESSA Pharma Inc.9Q1 20186.5%
Aerie Pharmaceuticals Inc.7Q4 201530.5%
VBI Vaccines Inc.7Q1 20169.1%
Ophthotech Corp6Q1 201531.5%

View Clarus Ventures, LLC's complete holdings history.

Latest filings
TypeFiled
13F-NT2024-02-14
13F-NT2023-11-14
13F-NT2023-08-14
13F-NT2023-05-15
13F-NT2023-02-14
13F-NT2022-11-14
13F-NT2022-08-15
13F-NT2022-05-16
13F-NT2022-02-14
13F-NT2021-11-15

View Clarus Ventures, LLC's complete filings history.

Compare quarters

Export Clarus Ventures, LLC's holdings